Atorvastatin contraindications: Difference between revisions
Gerald Chi (talk | contribs) m Changed protection level for "Atorvastatin contraindications" ([Edit=Allow only autoconfirmed users] (expires 17:41, 13 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 17:41, 13 February 2014 (UTC))) |
No edit summary |
||
| Line 1: | Line 1: | ||
{{CMG}} | __NOTOC__ | ||
{{Atorvastatin}} | |||
{{CMG}}; {{AE}} {{PB}} | |||
Atherosclerosis is a chronic process and discontinuation of lipid lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of [[primary hypercholesterolemia]]. | |||
[[Atherosclerosis]] is a chronic process and discontinuation of lipid lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of [[primary hypercholesterolemia]]. | |||
[[Cholesterol]] and other products of [[cholesterol biosynthesis]] are essential components for fetal development (including synthesis of steroids and cell membranes). Since [[HMG-CoA reductase inhibitor]]s decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, [[HMG-CoA reductase inhibitor]]s are contraindicated during pregnancy and in nursing mothers. | [[Cholesterol]] and other products of [[cholesterol biosynthesis]] are essential components for fetal development (including synthesis of steroids and cell membranes). Since [[HMG-CoA reductase inhibitor]]s decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, [[HMG-CoA reductase inhibitor]]s are contraindicated during pregnancy and in nursing mothers. | ||
Revision as of 18:07, 30 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
Atherosclerosis is a chronic process and discontinuation of lipid lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hypercholesterolemia.
Cholesterol and other products of cholesterol biosynthesis are essential components for fetal development (including synthesis of steroids and cell membranes). Since HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, HMG-CoA reductase inhibitors are contraindicated during pregnancy and in nursing mothers.
Atorvastatin should be administered to women of childbearing age only when such patients are highly unlikely to conceive and have been informed of the potential hazards.
If the patient becomes pregnant while taking this drug, therapy should be discontinued and the patient apprised of the potential hazard to the fetus.
Contraindications of Atorvastatin
Active liver disease or unexplained persistent elevations of serum transaminases
Hypersensitivity to any component of this medication
Pregnancy and Lactation
Adapted from the FDA Package Insert.